Presentation is loading. Please wait.

Presentation is loading. Please wait.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed.

Published byΣκύλλα Παπακώστας Modified over 5 years ago

Similar presentations

Presentation on theme: "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed."— Presentation transcript:

1 Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC  Fabrice Barlesi, MD, PhD, Edward B. Garon, MD, Dong-Wan Kim, MD, Enriqueta Felip, MD, Ji-Youn Han, MD, Joo-Hang Kim, MD, Myung-Ju Ahn, MD, Mary Jo Fidler, MD, Matthew A. Gubens, MD, Gilberto de Castro, PhD, Veerle Surmont, MD, Qiao Li, PhD, Anne C. Deitz, PhD, Gregory M. Lubiniecki, MD, Roy S. Herbst, MD  Journal of Thoracic Oncology  Volume 14, Issue 5, Pages (May 2019) DOI: /j.jtho Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Proportion of patients with deteriorated or improved status in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 scores at week 12 in patients with NSCLC tumor proportion score 1% or greater. Multiple imputation based on missing at random assumption was used. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Change from baseline to week 12 in (A) European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (EORTC QLQ-C30) and (B) European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) symptoms in patients with programmed death-ligand 1 tumor proportion score 1% or greater (full analysis set population) treated with pembrolizumab 2 mg/kg or docetaxel. Error bars are 95% confidence intervals. Q3W, every 3 weeks. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4 Supplementary Figure 1A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

5 Supplementary Figure 1B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplementary Figure 2A
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

7 Supplementary Figure 2B
Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

8 Supplementary Figure 3 Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed."

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management  Delphine Trousse, MD, Fabrice Barlesi,

Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management  Delphine Trousse, MD, Fabrice Barlesi,
Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.

Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Similar presentations

Ads by Google